BriaCell Therapeutics Ratios and Metrics

Market cap in millions CAD. Fiscal year is August - July.

Millions CAD. Fiscal year is Aug - Jul.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 24, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021
Market Cap	44	19	19	140	128	98
Market Cap Growth	476.61%	1.03%	-86.55%	9.34%	30.61%	1321.87%
Enterprise Value	11.83	-6.49	17.22	111.96	75.44	26.58
Last Close Price	5.03	10.10	154.50	1314.00	1257.76	963.00
PB Ratio	1.37	0.77	-5.72	-28.09	9.67	2.84
P/TBV Ratio	0.68	0.24	-	-	12.87	1.06
EV/EBITDA Ratio	-	0.17	-	-	-	-
EV/EBIT Ratio	-	0.17	-	-	-	-
EV/FCF Ratio	-	0.17	-	-	-	-
Net Debt / Equity Ratio	-0.95	-1.00	0.36	5.63	-3.97	-2.07
Net Debt / EBITDA Ratio	0.77	0.66	0.03	0.91	2.69	8.23
Net Debt / FCF Ratio	0.74	0.63	0.04	0.90	3.29	7.39
Quick Ratio	7.07	5.01	0.49	14.96	43.64	102.88
Current Ratio	7.07	5.01	0.49	14.96	45.00	103.81
Return on Equity (ROE)	-190.19%	-362.56%	152.63%	-619.75%	-141.25%	-114.78%
Return on Assets (ROA)	-162.91%	-197.69%	-201.78%	-66.74%	-30.39%	-23.82%
Return on Invested Capital (ROIC)	-2038.57%	-1380.42%	-1053.18%	-989.19%	-3640.60%	-1844.83%
Return on Capital Employed (ROCE)	-194.77%	-338.31%	-280.40%	-69.47%	-30.85%	-25.82%
Buyback Yield / Dilution	-1260.31%	-285.70%	-5.35%	-0.81%	-242.82%	-
Total Shareholder Return	-1260.31%	-285.70%	-5.35%	-0.81%	-242.82%	-